A California jury unanimously ruled in favor of ImprimisRx in a trademark infringement lawsuit filed against OSRX and its related party Ocular Science, according to a press release.
The jury awarded $34.9 million in damages, including $20.4 million in punitive damages and $14.5 million in actual damages, according to the release issued by Harrow, the parent company of ImprimisRx.
Mark L. Baum, CEO of Harrow, said in the release that the company is pleased with the verdict.
“It goes without saying that, having now successfully defended our intellectual property, at great time and expense,